Biden's Plan Expands Medicare, Medicaid to Cover Anti-Obesity Drugs
TL;DR Summary
The Biden administration has proposed expanding Medicare and Medicaid coverage to include costly anti-obesity drugs, potentially benefiting 7.4 million Americans. This move could significantly reduce out-of-pocket expenses for some Medicare beneficiaries, though the proposal's details and its future under the incoming Trump administration remain uncertain. The high cost of these drugs, such as Wegovy, has limited access, and the expansion could increase Medicare costs by billions annually. Currently, only a few states and job-based insurance plans cover these medications.
- 7.4 million Americans could gain Medicare or Medicaid coverage for anti-obesity drugs under Biden proposal CNN
- Obesity Drugs Would Be Covered by Medicare and Medicaid Under Biden Proposal The New York Times
- Biden proposes massive expansion of US weight-loss drug coverage Financial Times
- Biden proposes Medicare and Medicaid cover costly weight-loss drugs for millions of obese Americans The Associated Press
- Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs Fox News
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
3 min
vs 4 min read
Condensed
87%
605 → 79 words
Want the full story? Read the original article
Read on CNN